Everolimus Stent in Patients With Coronary Artery Disease (CAD)

Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease

Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients

Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.

Inclusion Criteria:

• All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)

Exclusion Criteria:

• Contraindication to dual antiplatelet therapy for 12 months
• Known allergy to sirolimus or everolimus
• Major surgical procedure planned within 1 month
• History, symptoms, or findings suggestive of aortic dissection.
• Participation in other trials
• Pregnancy